Gilead Sciences, Inc. (NASDAQ:GILD) Canada Supports Community Leaders With Local Hepatitis C Micro-Elimination Efforts

0
484
Gilead Sciences Inc.

Gilead Sciences, Inc. (NASDAQ:GILD) Canada has vowed to offer financial support towards screening and linkage to care projects across Canada. The primary focus will be on hepatitis C screening within high-risk patient populations. The initiative is in line with Canada’s commitment to rally behind World Health Organization’s (WHO) goal of eradicating chronic hepatitis C infection by 2030.

Among those who will benefit from the 13 Hepatitis C Micro-Elimination Grants, awarded to projects, including First Nations, people who inject drugs, prisoners, people with HIV infection, and immigrants.

It will take more than science to eliminate the burden of hepatitis C

Doing away with hepatitis C on patients will not be a walk in the park according to Gilead Canada. It has nothing to do with science or health systems. Instead, it is about taking collective steps in helping WHO realize its 2030 goal.

Currently, there is limited access to treatment by people with hepatitis C. However, Associate Professor of Medicine, the University of Ottawa, Dr. Curtis Cooper notes, “we must act now to identify patients and link them to care in order to reduce the risk of transmission, and ultimately, eliminate the disease.”

There will be regional correctional centers

People with hepatitis C can access multidisciplinary professionals from correctional for screening. In any case treatment with high cure rates across all genotypes is publicly available. There will also need to implement successful programs across the country. All said and done, Gilead Canada is passionate about being part of the solutions for the hepatitis C community.

Meanwhile, Norbert Bischofberger has indicated his intention of stepping down from his roles as an Executive Vice President, Research and Development and Chief Scientific Officer. Dr. Bischofberger joined the company 30years ago and has overseen the development of more than 25 compounds. Apparently all of them are readily available for a variety of serious medical conditions.

Other changes within the company include the appointment of Andrew Cheng to the position of Chief Medical Officer. The current MD and Executive Vice President, Clinical Research, John McHutchison will take up the responsibility for the company’s research and development organization.

LEAVE A REPLY

Please enter your comment!
Please enter your name here